Sunday, 22 April 2018 - 22:56
  • it
  • de
  • en
  • fr

Tresiba

Sanofi’s Toujeo bests Tresiba in clinical trial with 929 patients

Sanofi has announced today that its insulin Toujeo has met the primary endpoint vs Novo Nordisk’s insulin Tresiba (degludec) in the Bright clinical trial.  Bright has been conducted on 829 patients with type II diabetes and its complete results will…

Novo’s Tresiba approved in China

Novo Nordisk announced that the China Food and Drug Administration (CFDA) has approved Tresiba (insulin degludec) for diabetes treatment. The product is a basal, new-generation insulin, to be taken once daily, that provides an ultra-long duration of action. Tresiba has…

The best drug is not always a guarantee for the best financial results

Novo Nordisk demonstrated to investors and analysts that the best and most advanced drug is not always the product which ensures the best financial results. The Denmark-based pharmaceutical giant recently launched on the market Tresiba, a novel, advanced insulin for…

FDA approves pediatric use of Novo’s Tresiba

Novo Nordisk announced that FDA has extended the use of Tresiba (degludec) to children one year of age and older. The product is a basal, long-acting insulin to be administered once-daily to patients with type 1 and type 2 diabetes,…

Tresiba, Novo Nordisk announces results from DEVOTE trial

Novo Nordisk announced the results from DEVOTE, a long-term, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba (degludec) vs glargine U100 when added to standard of care. More than 7,500 people with type 2 diabetes at…